Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: October 2007
-
By Donald Zuhn — Yesterday, we reported on a second letter that was sent to the Office of Management and Budget (OMB) criticizing the IDS rules proposed by the U.S. Patent and Trademark Office on July 10, 2006 (see "Changes to Information Disclosure Statement Requirements and Other Related Matters," 71 Fed. Reg. 38,808). …
-
By Kevin E. Noonan — As reported recently by Patent Docs (see "Hooray! – (Finally) the Big Dogs Have Joined the Hunt"), GlaxoSmithKline (GSK) filed suit on October 9th in the U.S. District Court for the Eastern District of Virginia against John Dudas and the U.S. Patent and Trademark Office, asking for preliminary…
-
By Donald Zuhn — Last week, we reported on a letter that David Boundy, the Vice President of Intellectual Property for Cantor Fitzgerald L.P., sent to the Office of Management and Budget (OMB) on behalf of twenty-five companies and organizations, criticizing the IDS rules proposed by the U.S. Patent and Trademark Office on…
-
By Sherri Oslick — Genzyme Corporation of Cambridge, MA has announced that Bioenvision, Inc. (New York, NY) stockholders approved the acquisition of the company by Genzyme for roughly $345 million in cash. The acquisition suffered from a number of bumps in the road, starting with disapproval of the deal by a key stockholder…
-
By Kevin E. Noonan — Resistance to the U.S. Patent and Trademark Office’s new continuation and claims rules continues to grow (although how effective that resistance will be less than two weeks before the rules are implemented is a problematic question). The latest salvo comes from the Practising Law Institute’s Patent Blog, in…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sepracor Inc. et al. v. Dr. Reddy’s Laboratories, Ltd. et al.3:07-cv-05001; filed October 17, 2007 in the District Court of New Jersey…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Cobalt Pharmaceuticals Inc. et al. v. Bayer Aktiengesellschaft et al.1:07-cv-05875; filed October 17, 2007 in the Northern District of Illinois Declaratory judgment…
-
By Kevin E. Noonan — Earlier this year, Patent Docs had several posts relating to the use of an anticancer drug, Avastin® (bevacizumab, a monoclonal antibody), for treating neovascular or "wet" age-related macular degeneration (AMD), a condition that if untreated leads inexorably to blindness (see links below). This is an off-label use; another…
-
October 24, 2007 – "Sweeping USPTO Patent Rule Changes for Continuations and Claims: Strategies to Meet the New Obligations under the Complex Rules" (Strafford CLE Teleconferences) October 25-26, 2007 – Biotech and Pharma Public-Private Partnerships Forum (American Conference Institute) – Washington, D.C.*** October 25-27, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources…
-
By Donald Zuhn — On Monday, SparkIP launched a beta version of its new online intellectual property exchange, SparkIP.com. The site, which SparkIP describes as "an advanced research and commerce platform for the scientific community," is designed to connect scientists, inventors, licensors, licensees, corporations, universities, government labs, and patent attorneys with one another;…
Patent Docs 